Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis
"We are very pleased that IXIARO is now also approved by the Canadian authorities. This reflects another step in growing our IXIARO business by supplying this important product to travelers", states Gerd Zettlmeissl, Chief Executive Officer of Intercell.
Intercell's Japanese Encephalitis vaccine will be available for the Canadian market by the end of the year and will be distributed and marketed to travel clinics by Novartis Pharmaceuticals Canada Inc. and to the military personnel by Intercell.
IXIARO is a purified, inactivated product for active immunization against infection by the Japanese Encephalitis Virus. IXIARO is manufactured at Intercell's proprietary manufacturing facility in Scotland and is prepared using tissue culture rather than live organisms.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.